Long-term safety profile of siplizumab, a humanized anti-CD2 monoclonal antibody, in subjects with chronic plaque psoriasis

Internet Journal of Dermatology

Volumn 7, Issue 2, 2009, Pages

  White, Barbara ^a   Harris, Brian ^a  

^a MEDIMMUNE   (United States)

Author keywords

Clinical trial; Long term; Lymphocyte depletion; Psoriasis; Safety

Indexed keywords

SIPLIZUMAB;

ADULT; ARTICLE; BRONCHITIS; CHOLECYSTITIS; CHRONIC PLAQUE PSORIASIS; CLINICAL TRIAL; COLITIS; DRUG SAFETY; ENCEPHALITIS; FEMALE; FOLLOW UP; HUMAN; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; PSORIASIS;

EID: 77953397689     PISSN: None     EISSN: 15313018     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995; 1: 442-447. (s)
2. Branco L, Barren P, Mao SY, et al. Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells. Transplantation 1999; 68: 1588-1596. (s)
3. Bissonnette R, Langley RG, Papp K, Matheson R, Toth D, Hultquist M, Geba GP, White B. Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: Efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab. Arch Derm Res (Submitted). (s)
4. Ellis CN, Krueger GG, Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-255. (s)
5. Gordon KB, Vaishnaw AK, O'Gorman J, et al. Treatment of psoriasis with alefacept: Correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 2003; 139: 1563-1570. (s)
6. Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol. 2009 Jan 15. [Epub ahead of print]. (s)
7. Goffe B, Papp K, Gratton D, et al. An integrated analysis of thirteen trials summarizing the long term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 2005: 27: 1912-192. (s)